Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease

• Status: Terminated
• Trial end date: 2008-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to measure the effect of EGb 761® versus placebo on the ratio of the isoform of the protein precursor of beta amyloid platelets, in patients with mild to moderate Alzheimer's disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ipsen

Criteria

Inclusion Criteria:

• female or male of 50 to 85 years old with a care giver

• Mini Mental Status (MMS) test between 16 to 26 inclusive

• Clinical Dementia Rating (CDR) test inferior or equal to 1

• National Institute of Neurological and Communicative Disorders and Stroke / Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) test positive for an Alzheimer's disease

• Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM IV) test positive for dementia

Exclusion Criteria:

• patient already treated by medicines which could interfere with the study

• low level of vitamin B12 and folate which are considered as clinically relevant

• clinically relevant pathologies (eg: pulmonary illness, cardiovascular illness; evolutive cancer, neurological illness, blood illness….)